- Home
- NIPG vs ATOS Comparison
NIPG vs ATOS Comparison
Compare NIPG & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIPG
- ATOS
- Stock Information
- Founded
- NIPG 2014
- ATOS 2009
- Country
- NIPG Sweden
- ATOS United States
- Employees
- NIPG N/A
- ATOS N/A
- Industry
- NIPG
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- NIPG
- ATOS Health Care
- Exchange
- NIPG NYSE
- ATOS Nasdaq
- Market Cap
- NIPG 96.4M
- ATOS 107.2M
- IPO Year
- NIPG 2024
- ATOS 2012
- Fundamental
- Price
- NIPG $2.41
- ATOS $0.94
- Analyst Decision
- NIPG Strong Buy
- ATOS Strong Buy
- Analyst Count
- NIPG 1
- ATOS 3
- Target Price
- NIPG $6.00
- ATOS $6.17
- AVG Volume (30 Days)
- NIPG 406.8K
- ATOS 1.5M
- Earning Date
- NIPG 04-30-2025
- ATOS 08-11-2025
- Dividend Yield
- NIPG N/A
- ATOS N/A
- EPS Growth
- NIPG N/A
- ATOS N/A
- EPS
- NIPG N/A
- ATOS N/A
- Revenue
- NIPG $85,266,306.00
- ATOS N/A
- Revenue This Year
- NIPG $11.25
- ATOS N/A
- Revenue Next Year
- NIPG $33.33
- ATOS N/A
- P/E Ratio
- NIPG N/A
- ATOS N/A
- Revenue Growth
- NIPG 1.91
- ATOS N/A
- 52 Week Low
- NIPG $0.99
- ATOS $0.55
- 52 Week High
- NIPG $17.76
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- NIPG N/A
- ATOS 58.44
- Support Level
- NIPG N/A
- ATOS $0.81
- Resistance Level
- NIPG N/A
- ATOS $0.88
- Average True Range (ATR)
- NIPG 0.00
- ATOS 0.05
- MACD
- NIPG 0.00
- ATOS 0.01
- Stochastic Oscillator
- NIPG 0.00
- ATOS 84.07
About NIPG NIP GROUP INC SPON ADS EACH REPR 2 CL A ORD SHS
NIP Group Inc is a digital entertainment company built for the growing gaming and esports industry. NIP Group integrates multiple businesses such as talent agency, event production, game-themed hotels and game publishing to create transformative entertainment experiences that inspire, connect fans, expand influence globally, and achieve deep interaction on platforms where digital native players gather. It currently has operation centers in Sweden, China, Abu Dhabi, and Brazil, and its esports teams cover multiple game projects and are active in the top event stages.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.